Phase 2 Open Label Study of Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects
Phase of Trial: Phase II
Latest Information Update: 08 Apr 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 03 Apr 2019 Planned End Date changed from 30 Sep 2020 to 30 Sep 2021.
- 03 Apr 2019 Planned primary completion date changed from 30 Sep 2019 to 30 Sep 2020.
- 31 Aug 2018 Biomarkers information updated